21:11 , Jan 23, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Other A gastric-resident method of delivering multiple antiretroviral (ART) agents together could treat HIV for prolonged periods with a single administration. The gastric-resident dosage form comprises six rigid arms allowing for the delivery of up...
01:21 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

Long-acting intramuscular cabotegravir: Ph III HPTN 083 started

ViiV began the 3-step, double-blind, international Phase III HPTN 083 trial to compare 600 mg long-acting intramuscular cabotegravir vs. once-daily oral Truvada tenofovir disoproxil fumarate/emtricitabine in 4,500 men and transgender women who have sex with...
16:15 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Cabotegravir: Ph III started

ViiV began the open-label, international Phase III FLAIR trial to evaluate switching to cabotegravir plus Edurant rilpivirine following a 20-week induction therapy with once-daily oral Triumeq dolutegravir/abacavir/lamivudine in about 600 treatment-naïve patients. After induction, patients...
16:15 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Cabotegravir: Ph III started

ViiV began the open-label, international Phase III ATLAS trial to evaluate switching to cabotegravir plus Edurant rilpivirine in about 570 patients who achieved viral suppression on a regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs)...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

J&J, Viiv Healthcare deal

Johnson & Johnson’s Janssen Biotech Inc. unit partnered co-exclusively with ViiV to globally develop and commercialize a combination regimen of long-acting, injectable formulations of HIV infection therapies Edurant rilpivirine and cabotegravir. Edurant, a marketed...
02:21 , Jan 8, 2016 |  BC Extra  |  Company News

J&J announces 22 partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled 22 new collaborations spanning the cancer, diabetes, rare diseases and consumer healthcare sectors. The Innovation unit also said it will start an external...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Cabotegravir: Phase IIb data

The 96-week, open-label, international Phase IIb LATTE 2 trial in 286 evaluable patients with HIV-1 infection showed that a long-acting intramuscular regimen of cabotegravir plus rilpivirine given every 4 or 8 weeks as suppressive maintenance...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Edurant rilpivirine: Phase IIb data

The 96-week, open-label, international Phase IIb LATTE 2 trial in 286 evaluable patients with HIV-1 infection showed that a long-acting intramuscular regimen of cabotegravir plus rilpivirine given every 4 or 8 weeks as suppressive maintenance...
02:15 , Nov 4, 2015 |  BC Extra  |  Company News

GSK aims for 20 filings by 2020

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said at its R&D day Tuesday that it hopes to submit up to 20 pipeline candidates for approval by 2020, with an additional 20 filings to follow in 2021-25. GSK highlighted...
07:00 , Apr 3, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV integrase Macaque studies suggest postcoital dosing of gel-formulated HIV integrase inhibitors could prevent HIV...